Join us for the Policy Summit Sept. 25-26 at the Washington Marriott Georgetown in Washington, D.C.!
This conversation explores Dr. Bell's recent MTNA publication "RNA Exon Editing: Splicing the Way to Treat Human Diseases."
Follow the ASGCT Podcast Network wherever you listen to podcasts!
Join Dr. Paloma Giangrande, Editor-in-Chief of Molecular Therapy Nucleic Acids, as she discusses RNA exon editing with Ascidian Therapeutics' leadership: CSO Dr. Robert Bell and CEO Dr. Michael Ehlers. Their conversation explores Dr. Bell's recent MTNA publication "RNA Exon Editing: Splicing the Way to Treat Human Diseases."
Last Call: Submit your abstracts for ASGCT's 2025 Annual Meeting in New Orleans by January 31st, 11:59 PM ET. Present at cell and gene therapy's premier event and get published in Molecular Therapy. Details at annualmeeting.asgct.org/abstracts.
In This Episode
Paloma Giangrande, PhD Editor-in-Chief, Molecular Therapy Nucleic Acids and Chief Technology Officer at Eleven Therapeutics
Robert Bell, PhD Chief Scientific Officer at Ascidian Therapeutics
Michael Ehlers, MD, PhD President and Chief Executive Officer at Ascidian Therapeutics
'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.au
Sept. 25-26, 2025 | Washington, D.C.
© 2000-2025 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico